Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Operating Expenses (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Operating Expenses for 5 consecutive years, with $4.5 million as the latest value for Q4 2020.

  • On a quarterly basis, Operating Expenses rose 114.82% to $4.5 million in Q4 2020 year-over-year; TTM through Dec 2020 was $46.3 million, a 1038.83% increase, with the full-year FY2024 number at $36.6 million, up 12.67% from a year prior.
  • Operating Expenses was $4.5 million for Q4 2020 at Forte Biosciences, down from $5.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $34.8 million in Q2 2020 to a low of -$30.3 million in Q4 2019.
  • A 5-year average of $9.2 million and a median of $8.6 million in 2017 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 258.63% in 2019, then surged 632.16% in 2020.
  • Forte Biosciences' Operating Expenses stood at $8.0 million in 2016, then skyrocketed by 33.95% to $10.7 million in 2017, then soared by 78.72% to $19.1 million in 2018, then tumbled by 258.63% to -$30.3 million in 2019, then soared by 114.82% to $4.5 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Operating Expenses are $4.5 million (Q4 2020), $5.0 million (Q3 2020), and $34.8 million (Q2 2020).